The trial is taking place at:
S

Somaiya Vidyavihar University | K.J Somaiya Hospital and Research Centre

Veeva-enabled site

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1)

Novo Nordisk logo

Novo Nordisk

Status and phase

Enrolling
Phase 2

Conditions

Sickle Cell Disease

Treatments

Drug: NDec - oral decitabine-tetrahydrouridine
Drug: HU - Hydroxyurea
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05405114
U1111-1255-1324 (Other Identifier)
NN7533-4470
2020-003485-39 (EudraCT Number)

Details and patient eligibility

About

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who are not taking Hydroxyurea (HU) will get NDec, NDec and placebo, or placebo. Participants who are on HU treatment before joining the study will get NDec, NDec and placebo, or continue on HU. Which treatment participants get is decided by chance. Participants getting NDec and/or Placebo will get capsules to take twice weekly. The study will last for about a year.

Enrollment

84 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age above or equal to 18 years at the time of signing informed consent
  • Confirmed diagnosis of SCD (including HbSS, HbSC, HbSβ0 thalassaemia and HbSβ+ thalassaemia or other Sickle Cell disease variants)
  • 2-10 episodes of documented vaso-occlusive crisis (VOCs) within the last 12 months prior to the screening visit
  • Haemoglobin greater than or equal to 5.0 g/dL and below or equal to 10.5 g/dL at visit 1
  • Absolute reticulocyte count above upper limit of the normal (ULN) at visit 1
  • Body weight 40 to 125 kg (inclusive).

Exclusion criteria

  • Patient is on chronic transfusion therapy as defined by receiving scheduled (pre-planned) series of blood transfusion (simple or exchange) for prophylactic purposes, or the patient is likely to begin chronic transfusion therapy during the course of the trial, or has received RBC or whole blood transfusion for any reason within 28 days of visit 1
  • Receipt of erythropoietin or other haematopoietic growth factor treatment within 28 days of signing ICF, or planned treatment with these agents during the trial
  • Receipt of voxelotor, crizanlizumab or L-glutamine treatment within 12 weeks of signing the informed consent form, or planned treatment with such agents during the trial
  • Platelet count greater than 800 x 10^9/L at visit 1
  • Absolute neutrophil count below or equal to 1.5 x 10^9/L at visit 1
  • Any condition/concurrent chronic disease involving the stomach or small intestine which may affect drug absorption, as per investigator's judgement

Female who is

  • pregnant, breast-feeding or intends to become pregnant within 6 months after the final trial product administration
  • child-bearing potential and not using highly effective methods of contraception and whose male partner is not using effective contraception, at screening and until 6 months after the last dose of trial product

Male with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure from trial start to:

  • Six (6) months after the last dose of trial product for patients on NDec/Placebo
  • Six (6) months after the last dose of trial product for patients outside US and CA randomised to HU
  • Twelve (12) months after the last dose of trial product for patients randomised to HU in US and CA

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

84 participants in 6 patient groups, including a placebo group

HU-non-eligible - NDec plus placebo
Experimental group
Description:
HU-non eligible patients randomised to treatment with NDec on one day and placebo on the other day
Treatment:
Drug: Placebo
Drug: NDec - oral decitabine-tetrahydrouridine
HU-non-eligible - NDec plus NDec
Experimental group
Description:
HU-non eligible patients randomised to treatment with NDec on both days
Treatment:
Drug: NDec - oral decitabine-tetrahydrouridine
HU-non-eligible - Placebo plus placebo
Placebo Comparator group
Description:
HU-non eligible patients randomised to treatment with placebo on both days
Treatment:
Drug: Placebo
HU-active - NDec plus placebo
Experimental group
Description:
HU-active patients randomised to treatment with NDec on one day and placebo on the other day
Treatment:
Drug: Placebo
Drug: NDec - oral decitabine-tetrahydrouridine
HU-active - NDec plus NDec
Experimental group
Description:
HU-active patients randomised to treatment with NDec on both days
Treatment:
Drug: NDec - oral decitabine-tetrahydrouridine
HU-active - HU
Active Comparator group
Description:
HU-active patients randomised to continue on open-label HU treatment
Treatment:
Drug: HU - Hydroxyurea

Trial contacts and locations

64

Loading...

Central trial contact

Novo Nordisk

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems